Hypoxia signalling in cancer and approaches to enforce tumour regression

Nature

Volumn 441, Issue 7092, 2006, Pages 437-443

  Pouysségur, Jacques ^a   Dayan, Frédéric ^a   Mazure, Nathalie M ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; GLUCOSE; METABOLISM; NUTRITION;

HYPOXIA-INDUCIBLE FACTOR (HIF); SIGNAL CIRCUITRIES; STRESS SIGNALLING;

TUMORS;

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ANGIOPOIETIN 2; GUANOSINE TRIPHOSPHATASE; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; PROTEIN BNIP3; S6 KINASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN; PROTEIN KINASE;

CANCER; GENETIC VARIATION; GLUCOSE; HYPOXIA; METABOLISM; NUTRIENT; TUMOR;

ACIDOSIS; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; AUTOPHAGY; BETA CHAIN; CANCER INVASION; CANCER REGRESSION; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL INVASION; CELL PH; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; HYDROXYLATION; HYPOXIA; MICHAELIS CONSTANT; NONHUMAN; NUTRIENT SUPPLY; OXYGEN TENSION; PH; PHOSPHORYLATION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RNA STABILITY; TUBEROUS SCLEROSIS; TUMOR CELL; ANIMAL; CELL HYPOXIA; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL HYPOXIA; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 33745303045     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04871     Document Type: Review

References (102)

1. mapk are required for fibroblast proliferation. Proc. Natl Acad. Sci. USA 90, 8319-8323 (1993).
2. Pouyssegur, J. & Lenormand, P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur. J. Biochem. 270, 3291-3299 (2003).
3. Marshall, C. How do small GTPase signal transduction pathways regulate cell cycle entry? Curr. Opin. Cell Biol. 11, 732-736 (1999).
4. Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262-267 (1998).
5. Kinbara, K., Goldfinger, L. E., Hansen, M., Chou, F. L. & Ginsberg, M. H. Ras GTPases: integrins' friends or foes? Nature Rev. Mol. Cell Biol. 4, 767-776 (2003).
6. Rak, J. et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60, 490-498 (2000).
7. Berra, E., Pages, G. & Pouyssegur, J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19, 139-145 (2000).
8. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
9. Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 9, 677-684 (2003).
10. Wang, G. L. & Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237 (1995).
11. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578 (1999).
12. Ikeda, E., Achen, M. G., Breier, G. & Risau, W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270, 19761-19766 (1995).
13. Mandriota, S. J. & Pepper, M. S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res. 83, 852-859 (1998).
14. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
15. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
16. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669-676 (2003).
17. Maisonpierre, P. C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
18. Carmeliet, P. Blood vessels and nerves: common signals, pathways and diseases. Nature Rev. Genet. 4, 710-720 (2003).
19. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163-1177 (2003).
20. Pages, G. & Pouyssegur, J. Transcriptional regulation of the vascular endothelial growth factor gene: a concert of activating factors. Cardiovasc. Res. 65, 564-573 (2005).
21. Milanini-Mongiat, J., Pouyssegur, J. & Pages, G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277, 20631-20639 (2002).
22. Richard, D. E., Berra, E., Gothie, E., Roux, D. & Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274, 32631-32637 (1999).
23. Pages, G., Berra, E., Milanini, J., Levy, A. P. & Pouyssegur, J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J. Biol. Chem. 275, 26484-26491 (2000).
24. Huez, I. et al. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol. Cell Biol. 18, 6178-6190 (1998).
25. Lang, K. J., Kappel, A. & Goodall, G. J. Hypoxia-inducible factor-1α mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol. Biol. Cell 13, 1792-1801 (2002).
26. Hegen, A. et al. Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler. Thromb. Vasc. Biol. 24, 1803-1809 (2004).
27. Lindblom, P. et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 17, 1835-1840 (2003).
28. Noseda, M. et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol. Cell Biol. 24, 8813-8822 (2004).
29. Fiedler, U. et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103, 4150-4156 (2004).
30. Manalo, D. J. et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105, 659-669 (2005).
31. Brahimi-Horn, C., Mazure, N. & Pouyssegur, J. Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cell Signal. 17, 1-9 (2005).
32. Semenza, G. L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 19, 176-182 (2004).
33. Berra, E., Ginouves, A. & Pouyssegur, J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 7, 41-45 (2006).
34. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
35. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
36. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologsdefine a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
37. Kaelin, W. G. Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14, 2703-2711 (2003).
38. Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11, 293-299 (2001).
39. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y. & Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274, 6519-6525 (1999).
40. Berra, E., Richard, D. E., Gothie, E. & Pouyssegur, J. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation. FEBS Lett. 491, 85-90 (2001).
41. Berra, E. et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22, 4082-4090 (2003).
42. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002).
43. Gothie, E., Richard, D. E., Berra, E., Pages, G. & Pouyssegur, J. Identification of alternative spliced variants of human hypoxia-inducible factor-1α. J. Biol. Chem. 275, 6922-6927 (2000).
44. Koivunen, P., Hirsila, M., Gunzler, V., Kivirikko, K. I. & Myllyharju, J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279, 9899-9904 (2004).
45. Dayan, F., Roux, D., Brahimi-Horn, C., Pouyssegur, J. & Mazure, N. The oxygen-sensor factor inhibiting HIF-1 (FIH) controls the expression of distinct genes through the bi-functional transcriptional character of HIF-1α. Cancer Res. 66, 3688-3698 (2006).
46. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl Acad. Sci. USA 97, 9082-9087 (2000).
47. Webster, K. A., Graham, R. M. & Bishopric, N. H. BNip3 and signal-specific programmed death in the heart. J. Mol. Cell Cardiol. 38, 35-45 (2005).
48. Guertin, D. A. & Sabatini, D. M. An expanding role for mTOR in cancer. Trends Mol. Med. 11, 353-361 (2005).
49. Nobukini, T. & Thomas, G. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Novartis Found. Symp. 262, 148-154; Discussion 154-159, 265-268 (2004).
50. Brugarolas, J. & Kaelin, W. G. Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6, 7-10 (2004).
51. Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. & Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259-1268 (2003).
52. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. & Pandolfi, P. P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193 (2005).
53. Hara, K. et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273, 14484-14494 (1998).
54. Peng, T., Golub, T. R. & Sabatini, D. M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell Biol. 22, 5575-5584 (2002).
55. Fukuda, R. et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277, 38205-38211 (2002).
56. Thomas, G. V. et al. Hypoxia-indudble factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Med. 12, 122-127 (2006).
57. Shaw, R. J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329-3335 (2004).
58. Kahn, B. B., Alquier, T., Carling, D. & Hardie, D. G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25 (2005).
59. Hardie, D. G. New roles for the LKB1-AMPK pathway. Curr. Opin. Cell Biol. 17, 167-173 (2005).
60. Reiling, J. H. & Hafen, E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18, 2879-2892 (2004).
61. Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004).
62. Lum, J. J. et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120, 237-248 (2005).
63. Bacon, A. L. & Harris, A. L. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann. Med. 36, 530-539 (2004).
64. Okami, J., Simeone, D. M. & Logsdon, C. D. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 64, 5338-5346 (2004).
65. Manka, D., Spicer, Z. & Millhorn, D. E. Bcl-2/adenovirus E1B 19 kDa interacting protein-3 knockdown enables growth of breast cancer metastases in the lung, liver, and bone. Cancer Res. 65, 11689-11693 (2005).
66. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-53 (2005).
67. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
68. Funasaka, T., Yanagawa, T., Hogan, V. & Raz, A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J. 19, 1422-1430 (2005).
69. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
70. Staller, P. et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-311 (2003).
71. Thiery, J. P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15, 740-746 (2003).
72. Beavon, I. R. Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol. Pathol. 52, 179-188 (1999).
73. Imai, T. et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163, 1437-1447 (2003).
74. Esteban, M. A. et al. Cancer Res. 66, 3567-3575 (2006).
75. Thomassin, L. et al. The Pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers. J. Biol. Chem. 280, 42848-42855 (2005).
76. Peinado, H. et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24, 3446-3458 (2005).
77. Kirschmann, D. A. et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 62, 4478-4483 (2002).
78. Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006).
79. Denko, N. C. et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22, 5907-5914 (2003).
80. Krishnamachary, B. et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66, 2725-2731 (2006).
81. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-46 (2002).
82. Covello, K. L. et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557-570 (2006).
83. Kong, D. et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65, 9047-9055 (2005).
84. Ferrara, N. & Kerbel, R. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
85. Oliner, J. et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516 (2004).
86. Newell, K., Franchi, A., Pouyssegur, J. & Tannock, I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc. Natl Acad. Sci. USA 90, 1127-1131 (1993).
87. + exchanger in metastasis. Nature Rev. Cancer 5, 786-795 (2005).
88. Potter, C. & Harris, A. L. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3, 164-167 (2004).
89. 3-transporters. Pflügers Arch. 447, 495-509 (2004).
90. Halestrap, A. P. & Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflügers Arch. 447, 619-628 (2004).
91. Ullah, M. S., Davies, A. J. & Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α dependent mechanism. J. Biol. Chem. 281, 9030-9037 (2006).
92. + antiporter. Cell 56, 271-280 (1989).
93. + exchangers. J. Biol. Chem. 275, 1-4 (2000).
94. Pouyssegur, J., Franchi, A. & Pages, G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found. Symp. 240, 186-196; Discussion 196-198 (2001).
95. Wong, P., Kleemann, H. W. & Tannock, I. F. Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br. J. Cancer 87, 238-245 (2002).
96. Murray, C. M. et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nature Chem. Biol. 1, 371-376 (2005).
97. Lum, J. J., DeBerardinis, R. J. & Thompson, C. B. Autophagy in metazoans: cell survival in the land of plenty. Nature Rev. Mol. Cell Biol. 6, 439-448 (2005).
98. Kondo, Y., Kanzawa, T., Sawaya, R. & Kondo, S. The role of autophagy in cancer development and response to therapy. Nature Rev. Cancer 5, 726-734 (2005).
99. Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist 9 (suppl. 5), 10-17 (2004).
100. Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645-657 (2003).
101. Cummins, E. P. & Taylor, C. T. Hypoxia-responsive transcription factors. Pflügers Arch. 450, 363-371 (2005).
102. Gustafsson, M. V. et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628 (2005).